A B O U T U S
Biom Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for brain disorders.
Our mission is to improve human health and quality of life by developing innovative drugs for treating and possibly reversing the effects of hard-to-treat diseases such as rare epilepsies, Alzheimer’s disease and Autism. Biom’s initial focus is on rare pediatric epilepsy such as developmental and epileptic encephalopathies and Angelman syndrome.
PRODUCT PIPELINE
We have a product pipeline of clinical stage drug candidates targeting rare diseases including developmental and epileptic encephalopathies. Our lead product candidate Bio017 has proven to be generally safe and well tolerated in both acute and long-term use with preliminary evidence showing its effectiveness.
PRODUCT PIPELINE
We have a product pipeline of clinical stage drug candidates targeting rare diseases including developmental and epileptic encephalopathies. Our lead product candidate Bio017 has proven to be generally safe and well tolerated in both acute and long-term use with preliminary evidence showing its effectiveness.
2020: A TRANSFORMATIVE YEAR FOR BIOM THERAPEUTICS
2020: Critical Commercialization milestone completed
✓ Preclinical study published in Journal of Clinical Investigation
✓ Shows safety and efficacy data BIO017 in Angel Syndrome mouse model
✓ Clinical open label study show drug substance safety and preliminary efficacy profile
✓ Filed for Orphan Disease Designation for BIO017
✓ Securing patent rights for novel cannabinoid drug delivery
✓ Partnered with Canopy Growth and Alchem
2021: A Transformative Year for Biom Therapeutics
✓ IND-filing in Q1 2021
✓ Randomized Controlled Pivotal study of BIO017 in Angelman Syndrome
✓ Patients
2020: A TRANSFORMATIVE YEAR FOR BIOM THERAPEUTICS
Lead Drug Candidate: BIO017
✓ Developmental & epileptic encephalopathy syndromes – Phase 2 trial positive top-line data
✓ Angelman syndrome – preclinical safety and efficacy data
✓ 4Q 2021 DEE – Pivotal Phase 3 SATURN trial topline data
BIO018
✓ Alzheimer initial preclinical data
✓ HIV initial preclinical data
✓ Autism spectrum disorders preclinical data
Overview of
BIOM THERAPEUTICS
- Leading regional Company headquartered in Sarasota
- Experienced, professional senior management team
- Partnerships with Top Pharmaceutical Companies, Federal and State Agencies, and major Epilepsy Academic Centers
Overview of
BIOM THERAPEUTICS
- Leading regional Company headquartered in Sarasota
- Experienced, professional senior management team
- Partnerships with Top Pharmaceutical Companies, Federal and State Agencies, and major Epilepsy Academic Centers
PARTNERSHIP WITH US
Top Pharmaceutical Companies, Federal and State Agencies, and major Epilepsy Academic Centers
